Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

By Orio Francesco   Palomba Stefano   Cascella Teresa   Tauchmanovà Libuse   Nardo Luciano G.   Di Biase Sebastiano   Labella Donato   Russo Tiziana   Savastano Silvia   Tolino Achille   Zullo Fulvio   Colao Annamaria   Lombardi Gaetano  

Reproductive BioMedicine Online, Vol. 10, Iss. 2, 2005-02 ,pp. : 289-292

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

By Orio Francesco   Palomba Stefano   Cascella Teresa   Tauchmanovà Libuse   Nardo Luciano G   Di Biase Sebastiano   Labella Donato   Russo Tiziana   Savastano Silvia   Tolino Achille   Zullo Fulvio   Colao Annamaria   Lombardi Gaetano  

Reproductive BioMedicine Online, Vol. 9, Iss. 5, 2004-11 ,pp. : 505-510

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond

By  

Current Pharmaceutical Design, Vol. 17, Iss. 9, 2011-03 ,pp. : 908-921

Bentham Science Publishers

Access to resources Recommend Favorite

Polycystic ovary syndrome

By Franks Stephen  

Clinical Medicine, Vol. 32, Iss. 2, 1998-03 ,pp. : 111-113

Royal College Of Physicians

Access to resources Recommend Favorite

Risk factors for the deterioration of glucose metabolism in polycystic ovary syndrome

By Wang Jim X   Norman Robert J  

Reproductive BioMedicine Online, Vol. 9, Iss. 2, 2004-08 ,pp. : 201-204

Reproductive Healthcare Ltd

Access to resources Recommend Favorite